26 results
8-K
EX-99.2
CGTX
Cognition Therapeutics Inc
28 Jun 23
Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
7:27am
period and 3 in placebo period) Most common AEs by MedDRA system organ class: - GI: nausea, diarrhea - Injury & procedural complications: procedural
424B4
CGTX
Cognition Therapeutics Inc
14 Nov 22
Prospectus supplement with pricing info
6:02am
effects of our product candidates could result in patient injury or death. Any of these occurrences may materially and adversely affect our business … greater risk if we commercialize any products. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise
DRS
2gokmx25b3gkgq 90f
20 Oct 22
Draft registration statement
12:00am
10-K
57p4oahszyito
30 Mar 22
Annual report
7:40am
8-K
EX-99.1
kgdxow ww51x0uagu6
10 Jan 22
Regulation FD Disclosure
7:01am
10-Q
h57eydv
17 Nov 21
Quarterly report
5:15pm
424B4
z5v5j2
12 Oct 21
Prospectus supplement with pricing info
4:11pm
S-1
EX-10.18
ftjhpisfce3qdn67k
19 Jul 21
IPO registration
7:02am
S-1
EX-10.4
4s6mg4uuley0j8
19 Jul 21
IPO registration
7:02am
S-1
EX-10.6
rna3g
19 Jul 21
IPO registration
7:02am
S-1
EX-10.15
3e693
19 Jul 21
IPO registration
7:02am
S-1
EX-10.17
bektv67bow5pew 6v645
19 Jul 21
IPO registration
7:02am
S-1
fxlg7 bflt
19 Jul 21
IPO registration
7:02am